Vaccine reduces RSV disease in infants

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

Theme(s):
Adolescent Health

Author(s):

Prof Katherine L O'Brien, MD, Aruna Chandran, MDRobert Weatherholtz, BS, Hasan S Jafri, MD, M Pamela Griffin, MD, Terramika Bellamy, MS, Eugene V Millar, PhD, Kathryn M Jensen, MS, Brian S Harris, MS, Raymond Reid, MD, Lawrence H Moulton, PhD, Genevieve A Losonsky, Prof Ruth A Karron, MD, Prof Mathuram Santosham, MD

Published in:

The Lancet Infectious Diseases

Published Date:

12/01/2015

Original Publication Link

View here